BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a strong buy growth stock with a Buy rating and price target of $95.00 set by analyst William Pickering on August 19. Evercore ISI analyst Cory Kasimov also maintains a Buy rating with a price target of $110.00 on August 11.

The analyst consensus for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is Strong Buy, with a median price target of $57.48 suggesting a 70.49% upside potential. The company develops and commercializes therapies for serious medical conditions and rare diseases, with products like Valoctocogene roxaparvovec and Vosoritide in its pipeline.

While BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) presents investment potential, some believe AI stocks offer greater upside. For those interested in undervalued AI stocks, a free report on the best short-term AI stock is available. Check out Insider Monkey for more insights on potential stocks.

Disclosure: None. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: What Does Wall Street Think About BioMarin Pharmaceutical (BMRN)?